What's in Phytopharm Consulting Brazil's pipeline?

Phytopharm Consulting Brazil has 7 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Phytopharm Consulting Brazil's portfolio?

Top competitors by shared drug class: Geropharm, Shire, AbbVie (prior sponsor, Abbott), Addpharma Inc., Alexza Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/phytopharm-consulting-brazil.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Phytopharm Consulting Brazil — Portfolio Competitive Intelligence Brief

Phytopharm Consulting Brazil pipeline: 0 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
PIOLIN®	PIOLIN®	phase 3	Selective enzyme inhibitor	COX-2	Rheumatology
GAMALINE®	GAMALINE®	phase 3	Central nervous system stimulant		Psychiatry
NEDAX	NEDAX	phase 3	Serotonin receptor antagonist	5-HT2A receptor	Psychiatry
Aplause®	Aplause®	phase 3	S1P receptor modulator	S1PR1	Immunology
Cimicifuga Herbarium	Cimicifuga Herbarium	phase 3	Herbal extract / phytoestrogen		Women's Health / Menopause
Cimicifuga + Hiperico	Cimicifuga + Hiperico	phase 3	Herbal combination / phytotherapeutic agent		Women's Health / Menopause
GAMALINE® + HIPERICIN®	GAMALINE® + HIPERICIN®	phase 3	Phytopharmaceutical combination / Immunomodulator		Immunology / Inflammation

Therapeutic area mix

Psychiatry · 2
Women's Health / Menopause · 2
Immunology · 1
Immunology / Inflammation · 1
Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Geropharm · 2 shared drug classes
Shire · 2 shared drug classes
AbbVie (prior sponsor, Abbott) · 1 shared drug class
Addpharma Inc. · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Appello Pharmaceuticals, Inc. · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Phytopharm Consulting Brazil:

Cite this brief

Drug Landscape (2026). Phytopharm Consulting Brazil — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/phytopharm-consulting-brazil. Accessed 2026-05-16.